Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-cash Items (2021 - 2025)

ARS Pharmaceuticals' Non-cash Items history spans 5 years, with the latest figure at $42.4 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 3.16% year-over-year to $42.4 million; the TTM value through Dec 2025 reached $42.4 million, up 3.16%, while the annual FY2025 figure was $42.4 million, 3.16% up from the prior year.
  • Non-cash Items for Q4 2025 was $42.4 million at ARS Pharmaceuticals, down from $48.3 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $39.4 billion in Q1 2023 and bottomed at $4.5 million in Q1 2022.
  • The 5-year median for Non-cash Items is $44.2 million (2022), against an average of $4.7 billion.
  • The largest annual shift saw Non-cash Items skyrocketed 875193.2% in 2023 before it crashed 99.92% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $11.4 billion in 2021, then crashed by 99.47% to $60.4 million in 2022, then tumbled by 58.51% to $25.1 million in 2023, then skyrocketed by 63.89% to $41.1 million in 2024, then increased by 3.16% to $42.4 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Non-cash Items are $42.4 million (Q4 2025), $48.3 million (Q3 2025), and $53.9 million (Q2 2025).